NRF2 Anti-Oxidant Systems and White Matter Hyperintensities
NRF2 Anti-Oxidant Systems and White Matter Hyperintensities
批准号:
9256390
负责人:
Charles DeCarli
金额:
$61.24万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-15 至 2019-03-31
关键词:
AgeAlzheimer&aposs DiseaseAntioxidantsApoptosisAreaAutopsyBindingBloodBlood - brain barrier anatomyBlood VesselsBrainBrain InjuriesCell NucleusCerebrovascular DisordersCessation of lifeChronicClinicalClinical TrialsCognitiveCoupledCytoplasmDNADataDefense MechanismsDevelopmentDistantElderlyErythroidF2-IsoprostanesFutureGaitGene ExpressionGene TargetingGenesGoalsHealthHumanHypertensionImpaired cognitionImpairmentIndividualKnock-outKnockout MiceKnowledgeLeadLeukoencephalopathyMagnetic Resonance ImagingMeasuresMental DepressionModelingMutant Strains MiceMyelinMyelin SheathNF-E2-related factor 2NeurogliaNuclearOligodendrogliaOxidative StressPathogenesisPathologicPathologyPathway interactionsPatientsPermeabilityPlatelet Factor 4Quantitative Reverse Transcriptase PCRReactive Oxygen SpeciesResponse ElementsRiskRisk FactorsRoleSignal TransductionStaining methodStainsStem cellsSuperoxide DismutaseSystemTherapeutic InterventionTimeVascular DiseasesWhite Matter Hyperintensityage relatedaging populationattenuationbrain endothelial cellcatalasecell killingcerebral hypoperfusionglutathione peroxidaseimprovedin vivomyelin degenerationneuropathologynoveloligodendrocyte progenitoroxidationpreventpromoterpublic health relevanceresponsetherapeutic targettreatment trialwhite matter
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
White Matter Hyperintensities (WMH) are areas of discrete high signal intensity on T2 and FLAIR brain MRI. They are associated with increasing age, vascular disease and other factors and cause cognitive decline, depression and gait impairment. Since accrual of WMH may diminish with treatment of vascular risk factors, there is a potential for therapeutic intervention Recent studies of mutant mice show that knockout of the Nrf2 (Nuclear factor erythroid-derived 2-like 2) gene results in loss of brain myelin with a vacuolar leukoencephalopathy that occurs with advancing age. Nrf2 activates antioxidant response elements (ARE) to modulate downstream anti-oxidant target genes. These findings, coupled with our preliminary data showing increased expression of Nrf2 target genes in the blood of patients with WMH, has led us to focus this study on Nrf2 and propose these aims. Aim #1a: Demonstrate that the number of OLIGOs and OPCs in WMH identified by post-mortem MRI are decreased in WMH compared to distant unaffected white matter. Aim# 1b. Show that markers of oxidative stress, F2-isoprostane (myelin) and 8-OH-2dG (DNA), stain myelin sheaths and OLIGO nuclei in WMH compared to no staining in distant unaffected white matter. Aim# 1c. Demonstrate increased nuclear Nrf2 protein and increased Nrf2 target gene expression in WMH and at the margins of WMH as compared to distant unaffected white matter. Aim #2a: Demonstrate that expression of Nrf2 target genes in blood using qRT-PCR is increased in subjects with large volume WMH compared to those with low volume WMH as measured using in vivo MRI. Aim# 2b: Demonstrate that the expression of Nrf2 target genes using qRT-PCR is either persistently elevated or markedly increases in blood of subjects whose WMH volumes increase the most over 2 years compared to matched subjects who have the smallest changes in WMH volumes over 2 years. Aim #3. Demonstrate that brain pathological changes and Nrf2 target gene expression changes in blood and WMH in Aims #1 and #2 are present in the blood and brain obtained from the same individual. In this study we will determine whether systemic and brain oxidative stress correlate with WMH damage, large WMH volumes and progression of WMH volumes over time. Systemic ROS damage brain endothelial cells allowing pro-oxidant molecules into brain that increase brain ROS that contribute to WMH. This study will begin to identify novel Nrf2 therapeutic targets for decreasing or preventing WMH. It will also begin to provide the rationale and preliminary data needed before antioxidant trials would be undertaken to reduce WMH with the goal of delaying or preventing cognitive decline.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3389/fnagi.2014.00106
发表时间:
2014
期刊:
Frontiers in aging neuroscience
影响因子:
4.8
作者:
[Fletcher E, Carmichael O, Pasternak O, Maier-Hein KH, DeCarli C]
通讯作者:
DeCarli C
DOI:
10.3389/fnagi.2018.00042
发表时间:
2018
期刊:
Frontiers in aging neuroscience
影响因子:
4.8
作者:
[Zhan X, Stamova B, Sharp FR]
通讯作者:
Sharp FR
DOI:
10.1002/ana.23956
发表时间:
2013-10
期刊:
ANNALS OF NEUROLOGY
影响因子:
11.2
作者:
[Jackson, Kaleena, Barisone, Gustavo A., Diaz, Elva, Jin, Lee-way, DeCarli, Charles, Despa, Florin]
通讯作者:
Despa, Florin
DOI:
10.1007/s11065-014-9268-3
发表时间:
2014-09
期刊:
NEUROPSYCHOLOGY REVIEW
影响因子:
5.8
作者:
[Lockhart, Samuel N., DeCarli, Charles]
通讯作者:
DeCarli, Charles
DOI:
10.1212/wnl.0000000000003391
发表时间:
2016-11-29
期刊:
Neurology
影响因子:
9.9
作者:
[Zhan X, Stamova B, Jin LW, DeCarli C, Phinney B, Sharp FR]
通讯作者:
Sharp FR
共 6 条
Do Atmospheric Ultrafine Particles Lodge in the Brain and Cause Cognitive Decline Leading to Alzheimer's Disease Related Dementias?
-
批准号:10591354
-
项目类别:
-
资助金额:$209.43万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's disease
-
批准号:10629449
-
项目类别:
-
资助金额:$576.35万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's disease
-
批准号:10370841
-
项目类别:
-
资助金额:$667.95万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Early and life course socioeconomic adversity and dementia risk in Hispanics/Latinos
-
批准号:10445900
-
项目类别:
-
资助金额:$144.18万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Early and life course socioeconomic adversity and dementia risk in Hispanic/Latinos
-
批准号:10831329
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10461121
-
项目类别:
-
资助金额:$54.1万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Research Center
-
批准号:10461120
-
项目类别:
-
资助金额:$317.86万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Research Center
-
批准号:10666428
-
项目类别:
-
资助金额:$318.85万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Neuroimaging Core
-
批准号:10461128
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Neuroimaging Core
-
批准号:10666453
-
项目类别:
-
资助金额:$20.75万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10666429
-
项目类别:
-
资助金额:$54.27万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Research Center
-
批准号:10264660
-
项目类别:
-
资助金额:$312.92万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Neuroimaging Core
-
批准号:10264667
-
项目类别:
-
资助金额:$20.36万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10264661
-
项目类别:
-
资助金额:$53.25万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Core Center
-
批准号:10012518
-
项目类别:
-
资助金额:$6.99万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)
-
批准号:10489289
-
项目类别:
-
资助金额:$950.31万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10266150
-
项目类别:
-
资助金额:$881.34万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10489290
-
项目类别:
-
资助金额:$342.78万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)
-
批准号:10266149
-
项目类别:
-
资助金额:$1321.22万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
Novel imaging and endothelial biomarkers of small vessel cerebrovascular disease
-
批准号:9356355
-
项目类别:
-
资助金额:$101.63万
-
财政年份:2016
-
负责人:Charles DeCarli
-
依托单位: